TGM2 and cranioectodermal dysplasia: In a recent systematic review and meta-analysis, we observed the pooled sensitivity and specificity of all POCTs (based on tTG or DGP or tTG + anti-gliadin antibodies) for diagnosing CeD to be 94.0% (95% CI, 89.9–96.5%) and 94.4% (95% CI, 90.9–96.5%), respectively.